Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer
Micro Abstract: This retrospective observational study assessed real-world treatment patterns and clinical outcomes among first-line MSI-H/dMMR metastatic colorectal cancer patients. Of 150 patients in the study cohort, 38.7% were treated with chemotherapy and 61.3% with chemotherapy + EGFR/VEGF inh...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294223000333 |
| _version_ | 1797732860937895936 |
|---|---|
| author | Mayur M. Amonkar Monica Chase Nicole M. Myer Tongtong Wang Vladimir Turzhitsky Alexander Spira |
| author_facet | Mayur M. Amonkar Monica Chase Nicole M. Myer Tongtong Wang Vladimir Turzhitsky Alexander Spira |
| author_sort | Mayur M. Amonkar |
| collection | DOAJ |
| description | Micro Abstract: This retrospective observational study assessed real-world treatment patterns and clinical outcomes among first-line MSI-H/dMMR metastatic colorectal cancer patients. Of 150 patients in the study cohort, 38.7% were treated with chemotherapy and 61.3% with chemotherapy + EGFR/VEGF inhibitor (EGFRi/VEGFi). Clinical outcomes were better among patients who received chemotherapy + EGFR/VEGF inhibitor than those who received chemotherapy. Introduction: Prior to pembrolizumab approval in first-line (1L) treatment of MSI-H/dMMR metastatic colorectal cancer (mCRC), patients were managed with chemotherapy with or without an EGFRi or VEGFi, agnostic of biomarker testing or mutation status. This study assessed real-world treatment patterns and clinical outcomes among 1L MSI-H/dMMR mCRC patients treated with standard of care (SOC). Patients and methods: Retrospective observational evaluation of patients ≥18 years diagnosed with stage IV MSI-H/dMMR mCRC who received community-based oncology care. Eligible patients were identified (01-Jun-2017 – 29-Feb-2020) and followed longitudinally until 31-Aug-2020/the last patient record/date of death. Descriptive statistics and Kaplan-Meier analyses were conducted. Results: Of 150 1L MSI-H/dMMR mCRC patients, 38.7% were treated with chemotherapy and 61.3% with chemotherapy + EGFRi/VEGFi. Accounting for censoring, the overall median real-world time to treatment discontinuation (95% CI) was 5.3 (4.4, 5.8) months; 3.0 (2.1, 4.4) and 6.2 (5.5, 7.6) months in the chemotherapy and chemotherapy + EGFRi/VEGFi cohorts, respectively. The combined median overall survival was 27.7 (23.2, not reached [NR]) months; 25.3 (14.5, NR) and 29.8 (23.2, NR) months in the chemotherapy and chemotherapy + EGFRi/VEGFi cohorts, respectively. The overall median real-world progression-free survival was 6.8 (5.3, 7.8) months; 4.2 (2.8, 6.1) and 7.7 (6.1, 10.2) months in the chemotherapy and chemotherapy + EGFRi/VEGFi cohorts, respectively. Conclusions: 1L MSI-H/dMMR mCRC patients receiving chemotherapy with EGFRi/VEGFi had better outcomes than those receiving only chemotherapy. An unmet need and opportunity to improve outcomes exists in this population that may be addressed by newer treatments like immunotherapies. |
| first_indexed | 2024-03-12T12:20:38Z |
| format | Article |
| id | doaj.art-6d365d29da024c2e9759671b9448161c |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-03-12T12:20:38Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-6d365d29da024c2e9759671b9448161c2023-08-30T05:54:19ZengElsevierCancer Treatment and Research Communications2468-29422023-01-0136100712Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancerMayur M. Amonkar0Monica Chase1Nicole M. Myer2Tongtong Wang3Vladimir Turzhitsky4Alexander Spira5Merck & Co., Inc., Rahway, NJ, United States of America; Corresponding author.Merck & Co., Inc., Rahway, NJ, United States of AmericaMerck & Co., Inc., Rahway, NJ, United States of AmericaMerck & Co., Inc., Rahway, NJ, United States of AmericaMerck & Co., Inc., Rahway, NJ, United States of AmericaOntada/US Oncology Research/Virginia Cancer Specialists, Fairfax, VA, United States of AmericaMicro Abstract: This retrospective observational study assessed real-world treatment patterns and clinical outcomes among first-line MSI-H/dMMR metastatic colorectal cancer patients. Of 150 patients in the study cohort, 38.7% were treated with chemotherapy and 61.3% with chemotherapy + EGFR/VEGF inhibitor (EGFRi/VEGFi). Clinical outcomes were better among patients who received chemotherapy + EGFR/VEGF inhibitor than those who received chemotherapy. Introduction: Prior to pembrolizumab approval in first-line (1L) treatment of MSI-H/dMMR metastatic colorectal cancer (mCRC), patients were managed with chemotherapy with or without an EGFRi or VEGFi, agnostic of biomarker testing or mutation status. This study assessed real-world treatment patterns and clinical outcomes among 1L MSI-H/dMMR mCRC patients treated with standard of care (SOC). Patients and methods: Retrospective observational evaluation of patients ≥18 years diagnosed with stage IV MSI-H/dMMR mCRC who received community-based oncology care. Eligible patients were identified (01-Jun-2017 – 29-Feb-2020) and followed longitudinally until 31-Aug-2020/the last patient record/date of death. Descriptive statistics and Kaplan-Meier analyses were conducted. Results: Of 150 1L MSI-H/dMMR mCRC patients, 38.7% were treated with chemotherapy and 61.3% with chemotherapy + EGFRi/VEGFi. Accounting for censoring, the overall median real-world time to treatment discontinuation (95% CI) was 5.3 (4.4, 5.8) months; 3.0 (2.1, 4.4) and 6.2 (5.5, 7.6) months in the chemotherapy and chemotherapy + EGFRi/VEGFi cohorts, respectively. The combined median overall survival was 27.7 (23.2, not reached [NR]) months; 25.3 (14.5, NR) and 29.8 (23.2, NR) months in the chemotherapy and chemotherapy + EGFRi/VEGFi cohorts, respectively. The overall median real-world progression-free survival was 6.8 (5.3, 7.8) months; 4.2 (2.8, 6.1) and 7.7 (6.1, 10.2) months in the chemotherapy and chemotherapy + EGFRi/VEGFi cohorts, respectively. Conclusions: 1L MSI-H/dMMR mCRC patients receiving chemotherapy with EGFRi/VEGFi had better outcomes than those receiving only chemotherapy. An unmet need and opportunity to improve outcomes exists in this population that may be addressed by newer treatments like immunotherapies.http://www.sciencedirect.com/science/article/pii/S2468294223000333Colorectal cancerdMMRMSI-HOverall survivalProgression-free survivalReal-world |
| spellingShingle | Mayur M. Amonkar Monica Chase Nicole M. Myer Tongtong Wang Vladimir Turzhitsky Alexander Spira Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer Cancer Treatment and Research Communications Colorectal cancer dMMR MSI-H Overall survival Progression-free survival Real-world |
| title | Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer |
| title_full | Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer |
| title_fullStr | Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer |
| title_full_unstemmed | Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer |
| title_short | Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer |
| title_sort | real world treatment patterns and clinical outcomes for chemotherapy based regimens in first line msi h dmmr metastatic colorectal cancer |
| topic | Colorectal cancer dMMR MSI-H Overall survival Progression-free survival Real-world |
| url | http://www.sciencedirect.com/science/article/pii/S2468294223000333 |
| work_keys_str_mv | AT mayurmamonkar realworldtreatmentpatternsandclinicaloutcomesforchemotherapybasedregimensinfirstlinemsihdmmrmetastaticcolorectalcancer AT monicachase realworldtreatmentpatternsandclinicaloutcomesforchemotherapybasedregimensinfirstlinemsihdmmrmetastaticcolorectalcancer AT nicolemmyer realworldtreatmentpatternsandclinicaloutcomesforchemotherapybasedregimensinfirstlinemsihdmmrmetastaticcolorectalcancer AT tongtongwang realworldtreatmentpatternsandclinicaloutcomesforchemotherapybasedregimensinfirstlinemsihdmmrmetastaticcolorectalcancer AT vladimirturzhitsky realworldtreatmentpatternsandclinicaloutcomesforchemotherapybasedregimensinfirstlinemsihdmmrmetastaticcolorectalcancer AT alexanderspira realworldtreatmentpatternsandclinicaloutcomesforchemotherapybasedregimensinfirstlinemsihdmmrmetastaticcolorectalcancer |